Resveratrol Shields the Epileptic Brain by Rewiring Ion Channel Genes, Rat Study Finds

A naturally occurring polyphenol found in grapes, red wine, and berries may do far more than fuel antioxidant headlines. A new animal study published in BMC Complementary Medicine and Therapies reports that resveratrol, a small molecule famous for its role in research on longevity, significantly blunted the development of epilepsy-like brain activity in rats while protecting the hippocampus, the seahorse-shaped structure deep in the temporal lobe where many seizures take hold. The work, led by Omer Unal of the University of Samsun and Nilufer Akgun-Unal of Ondokuz Mayis University, goes beyond simply showing that the compound helps. It maps, in unusual molecular detail, how resveratrol appears to reprogram the electrical and genetic machinery of neurons under seizure-inducing stress, offering one of the first in vivo demonstrations that a dietary polyphenol can tune the genes governing calcium handling and neuronal excitability during the slow process by which a normal brain becomes an epileptic one.

The researchers used a classic experimental strategy known as the pentylenetetrazol, or PTZ, kindling model. Kindling is a phenomenon in which repeated, subconvulsive stimulation of the brain progressively lowers the seizure threshold until full-blown seizures emerge spontaneously. It is widely regarded as one of the best laboratory approximations of how human temporal lobe epilepsy develops over months and years. In the study, thirty-two Wistar albino rats were divided into four groups. Two groups received PTZ at a dose of 35 milligrams per kilogram of body weight three days per week to induce kindling, while the control groups received equivalent volumes of saline. Half of the animals in each condition were also given resveratrol at 5 milligrams per kilogram per day by intraperitoneal injection for twenty-eight days. Twenty-four hours after the final injection, the team harvested brain tissue for a battery of molecular and histological analyses.

The behavioral and electrophysiological results were striking. Rats that received resveratrol alongside PTZ showed a dramatically longer delay before their first myoclonic jerk, the sudden muscle twitch that marks the earliest observable seizure manifestation, with the difference reaching a p-value of 0.0001. The treated animals also spent less time in the full seizure phase and displayed a markedly lower total spike count on electrocorticography, the technique of recording electrical activity directly from the surface of the brain. In practical terms, the polyphenol did not merely soften the symptoms of an already kindled brain; it slowed the kindling process itself, pushing back the point at which the animals’ neural circuits tipped into pathological synchrony.

Under the microscope, the protection was visible in the hippocampal CA1 region, a subfield of the hippocampus that is exquisitely vulnerable to seizure-driven damage and is a hallmark site of neuron loss in human epilepsy. Hematoxylin and eosin staining, the workhorse technique of histology that highlights cell nuclei and tissue architecture, revealed that PTZ-kindled rats suffered clear neuronal deterioration and inflammation in CA1. In the animals that also received resveratrol, tissue integrity was substantially preserved, with fewer signs of neuronal injury and a calmer inflammatory landscape. Because the hippocampus is central to memory formation as well as seizure generation, preserving its cellular architecture has implications that extend beyond seizure control to the cognitive decline that often accompanies chronic epilepsy.

To understand the mechanism, the team turned to sirtuin 1, or SIRT1, a NAD-dependent deacetylase enzyme that has become one of the most intensively studied stress-response regulators in biology. SIRT1 sits at the intersection of metabolism, inflammation, and cell survival, and resveratrol has long been described as one of its pharmacological activators. Immunofluorescence staining showed that PTZ kindling depleted SIRT1 levels in the hippocampus, consistent with the idea that repeated seizures overwhelm the brain’s endogenous protective machinery. Resveratrol treatment restored SIRT1 to near-normal levels, suggesting that the compound re-engages a cellular stress-response program that epilepsy had switched off.

At the same time, resveratrol suppressed the molecular signature of programmed cell death. Immunofluorescence revealed that PTZ elevated caspase-3, the central executioner enzyme of apoptosis, along with S100B, a protein released by glial cells that serves as a widely used biomarker of astrocyte activation and brain injury. Both markers fell significantly in the resveratrol-treated animals. Quantitative polymerase chain reaction confirmed the pattern at the transcript level: expression of caspase-3 and caspase-9, the initiator caspase that feeds into the executioner cascade, were both downregulated by resveratrol, while SIRT1 messenger RNA rose. Together, these data sketch a coherent pathway in which resveratrol activates SIRT1, and SIRT1 in turn restrains the apoptotic and glial responses that would otherwise dismantle hippocampal circuitry during epileptogenesis.

Perhaps the most novel finding concerns ion channels. The researchers measured the expression of three genes that directly govern the electrical behavior of neurons: SERCA2a, the sarco/endoplasmic reticulum calcium ATPase 2a, which pumps calcium back into intracellular stores and is essential for terminating calcium signals; CACNA1G, which encodes the alpha-1G subunit of T-type voltage-gated calcium channels, a channel family notorious for driving the rhythmic burst firing that underlies absence seizures and thalamocortical oscillations; and HCN2, a hyperpolarization-activated cyclic nucleotide-gated channel subunit that carries the current responsible for a neuron’s resting pacemaker activity. PTZ kindling disrupted the expression of all three. Resveratrol reversed those changes, significantly upregulating SERCA2a, CACNA1G, HCN2, and SIRT1 with p-values below 0.0001.

The significance of this ion channel result is hard to overstate. Intracellular calcium is the master currency of neuronal signaling, and its mishandling is a recurring theme in epilepsy, stroke, and neurodegenerative disease. Excess calcium triggers excitotoxicity, the process by which overstimulated neurons literally digest themselves, and it feeds forward into mitochondrial stress and apoptosis. By restoring SERCA2a, resveratrol appears to strengthen the cell’s ability to clear calcium from the cytoplasm, while the coordinated changes in CACNA1G and HCN2 suggest a recalibration of the channels that set neuronal firing thresholds. The authors describe this as the first in vivo evidence that resveratrol modulates these specific ion channel genes to control calcium balance and excitability during epileptogenesis, a claim that, if replicated, positions the polyphenol as something closer to a circuit-level neuromodulator than a generic antioxidant.

Several caveats deserve emphasis. The study was conducted in a rodent model with intraperitoneal dosing, and the dose used, 5 milligrams per kilogram per day, does not translate directly to human supplementation, particularly given resveratrol’s notoriously poor oral bioavailability. The kindling model captures certain features of acquired epilepsy but not others, and the paper reports results from a relatively small sample of thirty-two animals. The article was also shared early as an accepted, citable version subject to further editorial processing. None of this diminishes the internal consistency of the data, which align behavioral, electrophysiological, histological, protein-level, and transcript-level evidence around a single mechanistic story, but it does mean that clinical relevance remains a hypothesis rather than a conclusion.

Even so, the study lands at a moment of genuine unmet need. Roughly a third of people with epilepsy are resistant to existing antiseizure medications, which largely work by suppressing neuronal firing rather than by modifying the disease process itself. A compound that appears to act on epileptogenesis, the slow remodeling of brain circuits that turns a healthy brain into an epileptic one, rather than merely damping acute seizures, would represent a fundamentally different therapeutic strategy. Resveratrol’s safety profile in humans is comparatively well characterized, and its ability to cross the blood-brain barrier has been documented in prior work. The present findings do not justify self-treatment, and the authors themselves frame the work as mechanistic rather than clinical. But they do give researchers a concrete molecular target list, SIRT1, SERCA2a, CACNA1G, HCN2, and the caspase cascade, around which to design the next generation of neuroprotective experiments, whether those involve resveratrol itself, more potent SIRT1 activators, or drugs aimed directly at the calcium-handling machinery of the epileptic hippocampus.

Subject of Research: Neuroprotective effects of resveratrol on the hippocampus in a PTZ-kindling model of epilepsy

Article Title: The effect of resveratrol on the hippocampus in the pentylenetetrazol (PTZ) – dependent kindling model of epilepsy

Article References: Unal, O., Akgun-Unal, N., Tiryaki, E. S., Gulbahce-Mutlu, E., Simsek, S., & Dasdelen, D. (2026). The effect of resveratrol on the hippocampus in the pentylenetetrazol (PTZ) – dependent kindling model of epilepsy. BMC Complementary Medicine and Therapies. https://doi.org/10.1186/s12906-026-05638-2

Image Credits: AI Generated

DOI: 10.1186/s12906-026-05638-2

Keywords: resveratrol, epilepsy, hippocampus, SIRT1, PTZ kindling, ion channels, apoptosis, SERCA2a, CACNA1G, HCN2, neuroprotection, calcium signaling